BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Oncothyreon Inc. 

2601 Fourth Avenue
Suite 500
Seattle  Washington  98121   U.S.A.
Phone: 206-801-2100 Fax: 206-801-2101


SEARCH JOBS




Industry
Biotechnology






 Company News
Oncothyreon Inc. (ONTY) Announces Merck KGaA (MKGAF.PK), Darmstadt, Germany, Initiation Of Phase 3 Start2 Study With Tecemotide In Stage III Non-Small Cell Lung Cancer 4/7/2014 9:35:30 AM    More...
Oncothyreon Inc. (ONTY) Reports Full Year And Fourth Quarter 2013 Financial Results 3/14/2014 6:23:56 AM    More...
Oncothyreon Inc. (ONTY) Announces Full Year And Fourth Quarter 2013 Financial Results Conference Call 3/6/2014 6:58:17 AM    More...
Oncothyreon Inc. (ONTY) To Present At Cowen and Company 34th Annual Health Care Conference 2/26/2014 6:39:35 AM    More...
Oncothyreon Inc. (ONTY) And Array BioPharma, Inc. (ARRY) Announce Initiation Of Phase 1b Trial Of ONT-380 In Combination With TDM-1 In Patients With Metastatic HER2+ Breast Cancer 2/20/2014 9:50:15 AM    More...
Oncothyreon Inc. (ONTY) And Array BioPharma, Inc. (ARRY) Announce Initiation Of Phase 1b Trial Of ONT-380 In Combination With Capecitabine And/Or Trastuzumab In Patients With Metastatic HER2+ Breast Cancer 2/3/2014 10:59:23 AM    More...
Oncothyreon Inc. (ONTY) Reports Third Quarter 2013 Financial Results 11/13/2013 8:59:42 AM    More...
Oncothyreon Inc. (ONTY) Announces Presentation of Data From Phase 1Trial of ONT-10 11/8/2013 10:03:14 AM    More...
Oncothyreon Inc. (ONTY) Announces Third Quarter 2013 Financial Results Conference Call 11/4/2013 7:03:01 AM    More...
Oncothyreon Inc. (ONTY) Announces Presentation of Final Results from Phase 1 Trial of ONT-380 10/7/2013 7:06:28 AM    More...
12345678910...